Los Angeles, CA, USA, May 5th, 2022 – ImaginAb, Inc., a market leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals (RPT), is pleased to announce it has signed a new multi-year, non-exclusive supply agreement with Genmab A/S, an international biotechnology company. Read more…
Turku, Finland – 28 March 2022: – DelSiTech Ltd, the leading silica drug delivery technology company, based in Finland and Optifye Therapeutics AG, a Swiss-based pharmaceutical company focusing on the development and commercialization of treatments for ophthalmic indications, today announced an exclusive licensing agreement pertaining to the development of controlled-release dexamethasone eye drops utilizing DelSiTech™ Silica Matrix technology. Read more…
Europe’s leading central nervous system specialty company strengthens its management team in Ireland and reinforces its growth strategy Dusseldorf and Barcelona, March 15, 2022 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), today announces that Tom Coogan has been appointed Country Manager for Ireland. The appointment reinforces […]
